186 related articles for article (PubMed ID: 30867440)
1. Effects of Black Raspberries and Their Ellagic Acid and Anthocyanin Constituents on Taxane Chemotherapy of Castration-Resistant Prostate Cancer Cells.
Eskra JN; Schlicht MJ; Bosland MC
Sci Rep; 2019 Mar; 9(1):4367. PubMed ID: 30867440
[TBL] [Abstract][Full Text] [Related]
2. Lack of combination effects of soy isoflavones and taxane chemotherapy of castration-resistant prostate cancer.
Eskra JN; Schlicht MJ; Bosland MC
Prostate; 2019 Feb; 79(2):223-233. PubMed ID: 30345530
[TBL] [Abstract][Full Text] [Related]
3. Effects of Black Raspberries and Their Constituents on Rat Prostate Carcinogenesis and Human Prostate Cancer Cell Growth In Vitro.
Eskra JN; Dodge A; Schlicht MJ; Bosland MC
Nutr Cancer; 2020; 72(4):672-685. PubMed ID: 31402717
[TBL] [Abstract][Full Text] [Related]
4. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
Carbonetti G; Converso C; Clement T; Wang C; Trotman LC; Ojima I; Kaczocha M
Prostate; 2020 Jan; 80(1):88-98. PubMed ID: 31661167
[TBL] [Abstract][Full Text] [Related]
6. ERG induces taxane resistance in castration-resistant prostate cancer.
Galletti G; Matov A; Beltran H; Fontugne J; Miguel Mosquera J; Cheung C; MacDonald TY; Sung M; O'Toole S; Kench JG; Suk Chae S; Kimovski D; Tagawa ST; Nanus DM; Rubin MA; Horvath LG; Giannakakou P; Rickman DS
Nat Commun; 2014 Nov; 5():5548. PubMed ID: 25420520
[TBL] [Abstract][Full Text] [Related]
7. Black Raspberries and Protocatechuic Acid Mitigate DNFB-Induced Contact Hypersensitivity by Down-Regulating Dendritic Cell Activation and Inhibiting Mediators of Effector Responses.
Anderson K; Ryan N; Siddiqui A; Pero T; Volpedo G; Cooperstone JL; Oghumu S
Nutrients; 2020 Jun; 12(6):. PubMed ID: 32517233
[TBL] [Abstract][Full Text] [Related]
8. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
[TBL] [Abstract][Full Text] [Related]
9. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer.
Park SE; Kim HG; Kim DE; Jung YJ; Kim Y; Jeong SY; Choi EK; Hwang JJ; Kim CS
Invest New Drugs; 2018 Apr; 36(2):195-205. PubMed ID: 29110173
[TBL] [Abstract][Full Text] [Related]
10. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
11. The antimicrobial activity of fruits from some cultivar varieties of Rubus idaeus and Rubus occidentalis.
Krauze-Baranowska M; Majdan M; Hałasa R; Głód D; Kula M; Fecka I; Orzeł A
Food Funct; 2014 Oct; 5(10):2536-41. PubMed ID: 25131001
[TBL] [Abstract][Full Text] [Related]
12. Dietary Consumption of Black Raspberries or Their Anthocyanin Constituents Alters Innate Immune Cell Trafficking in Esophageal Cancer.
Peiffer DS; Wang LS; Zimmerman NP; Ransom BW; Carmella SG; Kuo CT; Chen JH; Oshima K; Huang YW; Hecht SS; Stoner GD
Cancer Immunol Res; 2016 Jan; 4(1):72-82. PubMed ID: 26603620
[TBL] [Abstract][Full Text] [Related]
13. Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer.
Kroon J; Kooijman S; Cho NJ; Storm G; van der Pluijm G
Trends Pharmacol Sci; 2016 Jun; 37(6):451-462. PubMed ID: 27068431
[TBL] [Abstract][Full Text] [Related]
14. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
[TBL] [Abstract][Full Text] [Related]
15. Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells.
Souchek JJ; Davis AL; Hill TK; Holmes MB; Qi B; Singh PK; Kridel SJ; Mohs AM
Mol Cancer Ther; 2017 Sep; 16(9):1819-1830. PubMed ID: 28615298
[TBL] [Abstract][Full Text] [Related]
16. Taxane- and epothilone-based chemotherapy: from molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma.
Alberti C
Eur Rev Med Pharmacol Sci; 2013 Jun; 17(12):1658-64. PubMed ID: 23832735
[TBL] [Abstract][Full Text] [Related]
17. Tubulin-Binding 3,5-Bis(styryl)pyrazoles as Lead Compounds for the Treatment of Castration-Resistant Prostate Cancer.
Liao VWY; Kumari A; Narlawar R; Vignarajan S; Hibbs DE; Panda D; Groundwater PW
Mol Pharmacol; 2020 Jun; 97(6):409-422. PubMed ID: 32241960
[TBL] [Abstract][Full Text] [Related]
18. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.
Vrignaud P; Sémiond D; Lejeune P; Bouchard H; Calvet L; Combeau C; Riou JF; Commerçon A; Lavelle F; Bissery MC
Clin Cancer Res; 2013 Jun; 19(11):2973-83. PubMed ID: 23589177
[TBL] [Abstract][Full Text] [Related]
19. Targeting Nrf2-antioxidant signalling reverses acquired cabazitaxel resistance in prostate cancer cells.
Endo S; Kawai M; Hoshi M; Segawa J; Fujita M; Matsukawa T; Fujimoto N; Matsunaga T; Ikari A
J Biochem; 2021 Sep; 170(1):89-96. PubMed ID: 33729485
[TBL] [Abstract][Full Text] [Related]
20. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
Kato T; Mizutani K; Kameyama K; Kawakami K; Fujita Y; Nakane K; Kanimoto Y; Ehara H; Ito H; Seishima M; Deguchi T; Ito M
Urol Oncol; 2015 Sep; 33(9):385.e15-20. PubMed ID: 26027763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
